CYP2D6 multiallelism

被引：136
|
作者：
Daly, AK
Steen, VM
Fairbrother, KS
Idle, JR
机构：
[1] HAUKELAND HOSP, CTR MOL MED, DR EINAR MARTENS RES GRP BIOL PSYCHIAT, N-5021 BERGEN, NORWAY
[2] UNIV TRONDHEIM, FAC MED, INST CANC RES & MOL BIOL, N-7005 TRONDHEIM, NORWAY
来源：
CYTOCHROME P450, PT B | 1996年 / 272卷
关键词：
D O I：
10.1016/S0076-6879(96)72024-4
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：199 / 210
页数：12
相关论文
共 50 条
  • [21] Understanding CYP2D6 interactions
    de Groot, Marcel J.
    Wakenhut, Florian
    Whitlock, Gavin
    Hyland, Ruth
    DRUG DISCOVERY TODAY, 2009, 14 (19-20) : 964 - 972
  • [22] CYP2D6, serotonin and suicide
    Ahlner, Johan
    Zackrisson, Anna-Lena
    Lindblom, Bertil
    Bertilsson, Leif
    PHARMACOGENOMICS, 2010, 11 (07) : 903 - 905
  • [23] CYP2D6 genotyping and codeine
    De Leon, Jose
    PEDIATRIC ANESTHESIA, 2008, 18 (03) : 274 - 275
  • [24] CYP2D6 phenotyping with dextromethorphan
    Wojtczak, Anna
    Rychlik-Sych, Mariola
    Krochmalska-Ulacha, Eliza
    Skretkowicz, Jadwiga
    PHARMACOLOGICAL REPORTS, 2007, 59 (06) : 734 - 738
  • [25] PharmVar GeneFocus: CYP2D6
    Nofziger, Charity
    Turner, Amy J.
    Sangkuhl, Katrin
    Whirl-Carrillo, Michelle
    Agundez, Jose A. G.
    Black, John L.
    Dunnenberger, Henry M.
    Ruano, Gualberto
    Kennedy, Martin A.
    Phillips, Michael S.
    Hachad, Houda
    Klein, Teri E.
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 154 - 170
  • [26] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    de la Torre, R
    Farré, M
    Mathúna, BO
    Roset, PN
    Pizarro, N
    Segura, M
    Torrens, M
    Ortuño, J
    Pujadas, M
    Camí, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 551 - 554
  • [27] MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers
    Rafael de la Torre
    Magí Farré
    Brian Ó Mathúna
    Pere N. Roset
    Neus Pizarro
    Mireia Segura
    Marta Torrens
    Jordi Ortuño
    Mitona Pujadas
    Jordi Camí
    European Journal of Clinical Pharmacology, 2005, 61 : 551 - 554
  • [28] Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain
    Nahid, Noor Ahmed
    McDonough, Caitrin W.
    Wei, Yu-Jung Jenny
    Cicali, Emily J.
    Gong, Yan
    Fillingim, Roger B.
    Johnson, Julie A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 1005 - 1012
  • [29] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [30] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
12345